STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
STAT
JANUARY 31, 2023
Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its biosimilar version of Humira – the world’s best-selling medicine – and the numbers suggest the biggest winners may be health insurers and others in the supply chain, but not patients.
Let's personalize your content